Physician profile
Clint R Dunkle
NPI 1962842104
$3,588.23
in general payments reported to CMS, 2019-2025
39 companies · $631 in 2025
The $631 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $445 · 2020: $374 · 2021: $543 · 2022: $442 · 2023: $514 · 2024: $639 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,783.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $420.29 | 2020-2025 | Linzess, Qulipta, Viberzi |
| Astrazeneca Pharmaceuticals LP | $360.81 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $344.58 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $338.23 | 2019-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $326.85 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $204.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $148.44 | 2020-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Dexcom, INC. | $124.42 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.39 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.21 | 2019-2025 | Stiolto Respimat, Spiriva Respimat, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $90.43 | 2019-2024 | Trintellix |
| Abbott Laboratories | $88.11 | 2021-2025 | Freestyle Libre |
| Kowa Pharmaceuticals America, INC. | $83.02 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $79.08 | 2020-2025 | |
| Otsuka America Pharmaceutical, INC. | $68.21 | 2024-2025 | Rexulti |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clint Dunkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.